Skip Ribbon Commands
Skip to main content
Sign In
{{'GLOBAL_MESSAGE_HEADLINE' | translate}}
{{'GLOBAL_MESSAGE_CHOOSE_LANG' | translate}}
en
日本語
中文
{{'GLOBAL_MESSAGE_OR' | translate}}
{{'GLOBAL_MESSAGE_SET_COUNTRY' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM_CLOSE' | translate}}
{{'ELOQUA_BANNER_ACCEPT' | translate}}
{{'ELOQUA_BANNER_DECLINE' | translate}}

Why BMAC (Bone Marrow Aspirate Concentrate)?





More Consistent TNC Counts1

  • Lower variance produces higher confidence for clinicians.

Higher CFU-F Recovery1

  • The higher the cell recovery, the more cells are available for a surgeon to deliver to the application site.

High Concentrations of MSCs and HSCs

Higher cell concentration means more cells with potential healing power are delivered to the application site. The BMAC system generates higher concentrations of nucleated cells than an iliac crest autograft. The concentration of nucleated cells found in bone marrow aspirate generated from the BMAC system is 4.5 ± 0.5 times greater than the concentration of nucleated cells in unprocessed bone marrow aspirate.1

Healing Potential

  • The BMAC produced using the Terumo Blood and Cell Technologies BMAC Process Disposable and the SmartPrep® System contains a rich mixture of components including stem cells, progenitor cells, platelets, growth factors, lymphocytes and granulocytes.

Proven Consistency

Our biologic concentration technology provides clinicians and physicians with key advantages:
  • Consistently creates a purified, stem-cell-rich product with less variable TNC count1
  • Generates autologous biologic products without manual adjustments from patient to patient
  • Produces concentrated, ready-to-use biologics with a simple operation


Biologics: Make the Comparison

We have reviewed the literature and compiled the data to bring you a comparison of some common biologics.

Use Our Numbers to Improve Yours





Comparison of TNC Concentration




Composition of a Typical Sample Product From the BMAC System Using a 30 mL Procedure Pack4

Cell Type Cell Count
TNCs* 94.54 ± 37.7 × 103/µL
MNCs** 29.96 ± 12.61 × 103/µL
Platelets 540.13 ± 244.29 × 103/µL
Granulocytes 64.58 ± 26.94 × 103/µL

*TNCs = Total nucleated cells; platelets do not contain a nucleus

**MNCs = Mononculear cells



It takes more than just a spin in the centrifuge to achieve quality results. Terumo Blood and Cell Technologies' innovative floating shelf technology is behind the consistently reproducible results that clinicians can depend on.

Cell Capture Technology

The BMAC process disposable includes a proprietary, self-calibrating floating shelf that is designed for concentrating BMA. The floating shelf is designed with a specific density that concentrates the nucleated cells found in the bone marrow aspirate.


BMAC Total Nucleated Cell
(TNC) Count3
89 x 106/mL*

*89.1 ± 8 x 106/mL





Automated Processing

Combined with the BMAC Procedure Pack, the SmartPrep system automates point-of-care processing of biologics by:
  • Producing concentrated autologous biologics in 14 minutes' processing time5
  • Reducing the number of steps compared to a manual method
  • Simplifying training among multiple users

Watch the BMAC system in action.


Designed to Reduce Risk of Contamination

The disposables used with some other BMA systems have design features that can increase the risk of contamination. Our process disposables incorporate resealable injection ports that can be aseptically disinfected prior to entry. The process disposable design reduces the opportunity for contamination of the final product.
1Based on one study, publication in progress, where the BMAC system was compared to the Zimmer Biomet BioCUE® Blood and Bone Marrow Aspirate Concentration System and the Arthrex Angel® cPRP & Bone Marrow Processing System.

2Muschler G. Comparison of bone marrow aspiration and bone core biopsy as methods for harvest and assay of human connective tissue progenitor. Scientific paper 41; Presented at: 58th Association of Bone and Joint Surgeons Meeting; 2006.

3Hermann PC, Huber SL, Herrier T, et al. Concentration of bone marrow total nucleated cells by a point-of-care device provides a high yield and preserves their functional activity. Cell Transplant. 2008;16(10):1059-1069.

4Data on file.

5Terumo Blood and Cell Technologies. SmartPrep 3 Multicellular Processing System Operator's Manual. Terumo BCT, Inc., 2018. Part no. 514099557.


Risk Information: These procedures require needle access, possibly resulting in discomfort, tenderness, bruising, swelling, bleeding or pain at the access site, at which there is a small risk of infection. Lightheadedness, fainting, nausea or vomiting may occur. Before any medical procedure, review prescription and nonprescription medications and any natural or herbal remedies your patient is taking or plans to take.

​​​​​​​​​​

{{'SEARCH_MODAL_TITLE' | translate }}
{{'SEARCH_MODAL_OR' | translate }}

{{'SEARCH_MODAL_BROWSE' | translate }} {{'SEARCH_MODAL_ENLABEL' | translate }}
{{'SEARCH_MODAL_CHOOSE_LANGUAGE' | translate }} {{'SEARCH_MODAL_CHANGE_LANGUAGE' | translate }}
{{$index+1}}. {{s.label}}